ThomasS, Hard to actually elaborate on an idea based on no hard data but here are my thoughts. When collaborations are listed that accompany GTC announcements, Elan seems to be always causually mentioned. Most other erstwhile big pharma relationships are no longer on the list although at one point there were several. I believe GTC made tysabri for ELAN at one point and then the project was shelved but implications from previous company announcements were that it could be revived either because of saved sperm or founder goats (my speculation only) otherwise why would there be continued suble name dropping? Tysabri as a monoclonal is now approved for MS and Crohn's (I think approval has been finalized for the latter), in any case I can't help but wonder how attractive it might be for Elan to have endless supplies of tysabri available at a fraction of the current manufacturing costs, especially now that there is approval in Europe. The above is just based on recollections of announcements that are probably years old and may not be accurate, nonetheless I still see Elan and GTC in the same paragraph at times and wonder why the continued relationship. That's the best I can do--these thoughts are based on nothing substantial. Kind of like Seinfeld's show about nothing, but it sure had me in stitches (and they made a lot of money.) bp
Market Data 
Markets 
AI
